DGAP-Adhoc: Refusal of audit opinions for annual financial report 2020 (HGB) and consolidated annual financial report 2020 (IFRS); measures to secure further financing in implementation
DGAP-Ad-hoc: aap Implantate AG / Key word(s): Miscellaneous
Refusal of audit opinions for annual financial report 2020 (HGB) and consolidated annual financial report 2020 (IFRS); measures to secure further financing in implementation
29-Apr-2021 / 16:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG ("aap" or "Company") was informed at today's balance sheet meeting that the auditor Mazars GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Hamburg, will refuse the audit opinions for the annual financial report 2020 (HGB) and the consolidated annual financial report 2020 (IFRS). The background to this is that in the auditor's view up to the time of today's balance sheet meeting no sufficient evidence could be presented that aap's financing is secured for the twelve-month period. As a result, the auditor will declare the non-issuance of audit opinions due to an audit impediment and issue a note of refusal. In this case too, the Supervisory Board will adopt the annual financial statements (HGB) for the 2020 financial year and approve the consolidated financial statements (IFRS) for the 2020 financial year. The publication of the annual financial report 2020 (HGB) and the consolidated annual financial report 2020 (IFRS) is scheduled for April 30, 2021.
aap is still undergoing a comprehensive restructuring and refinancing process to secure further financing and thus the Company's continued existence. In this context, aap was already able to make noticeable progress in restructuring in financial year 2020, which is reflected, among other things, in a significantly improved recurring EBITDA (EUR -3.4 million; +28% vs. FY/2019) despite the enormous challenges posed by the COVID 19 pandemic. This improvement was mainly achieved through dynamic sales growth in the US (+41 % vs. FY/2019), an increased gross margin and a significantly reduced cost level. In addition, the Company was able to successfully implement the first two steps of the refinancing with a capital reduction and the issue of a convertible bond in the amount of EUR 2.6 million. In addition, aap has noticeably reduced the repayment amounts for the next few years by selling off excess capacity in its machinery and has raised shareholder loans of EUR 0.4 million.
In the first four months of financial year 2021, the focus was again on securing the Company's future financing. Further measures were implemented to ensure the continuity of the Company and to finance the planned growth and further development of the key technologies. In this context, at the end of March 2021 aap signed a purchase agreement with a Berlin real estate company for the sale of a plot of land in Brandenburg and qualified for the first time to receive state Corona aid under the COVID 19 aid program "Überbrückungshilfe III". aap has already received funds of EUR 0.5 million from the above financing measures, and further funds of around EUR 0.4 million will flow into the Company in the short term if both financing measures are successfully completed. In addition, the Management Board is currently working on the implementation of further measures and is confident that it will be able to implement them successfully and thus secure aap's financing over the next twelve months in line with current business planning.
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: [email protected]
29-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
||aap Implantate AG
||+49 (0) 30 75 01 90
||+49 (0) 30 75 01 91 11
||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
|EQS News ID:
|End of Announcement
||DGAP News Service
1190704 29-Apr-2021 CET/CEST
Quelle: boersengefluester.de und Firmenangaben
Die wichtigsten Finanzdaten auf einen Blick
|Ergebnis je Aktie8
Geschäftsbericht 2020 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
||Kurs in €
||Börsenwert in Mio. €
|Dividende '20 in €
||Dividende '21e in €
||Performance 52 Wochen